Physician profile
Krista J Fendrick
NPI 1316297286
$14,205.38
in general payments reported to CMS, 2019-2025
27 companies · $7,483 in 2025
The $7,483 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.59 · 2022: $299 · 2023: $960 · 2024: $5,403 · 2025: $7,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $422 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,408.77 |
| Education | $421.73 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,360.07 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $2,208.03 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,532.35 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,247.21 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,011.32 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $992.68 | 2024-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $938.06 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $806.28 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $708.16 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $609.18 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $439.75 | 2023-2025 | Rexulti |
| Noven Therapeutics, LLC | $376.42 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $186.43 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $179.23 | 2025 | Qelbree |
| Avadel Cns Pharmaceuticals, LLC | $122.86 | 2025 | Lumryz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $89.99 | 2024 | |
| Biogen, INC. | $79.53 | 2025 | Zurzuvae |
| Luye Pharma (USA) Ltd. | $41.65 | 2025 | Erzofri Extended-Release |
| Bausch Health US, LLC | $39.64 | 2024-2025 | Aplenzin |
| Lilly USA, LLC | $38.63 | 2024 | Kisunla |
| Ironshore Pharmaceuticals INC. | $35.56 | 2024 | |
| Collegium Pharmaceutical, INC. | $34.69 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $34.65 | 2024 | Nuplazid |
| Allergan, INC. | $29.99 | 2021 | |
| Corium, LLC | $28.71 | 2025 | Azstarys |
| Azurity Pharmaceuticals, INC. | $19.53 | 2024 | Horizant |
| Idorsia Pharmaceuticals US INC | $14.78 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Fendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.